Side-Effect Management

The Role of Pharmacogenetics in Ondansetron Failure in Pediatric Patients with CINV

By

Jennifer Larson

Researchers sought to determine what genetic factors may prompt a refractory response to ondansetron in pediatric patients with cancer.

Predictors of 28-Day Mortality Due to Septic Shock With Hematologic Malignancies

By

Jennifer Larson

Researchers sought to determine predictors for survival among hematologic cancer patients with septic shock.

Higher Symptom Burden More Likely to Improve With MPN Treatment

By

Vicki Moore, PhD

Analysis of data from 2 clinical trials sought to determine the effect on symptom burden of 2 common therapies for myeloproliferative neoplasms.

No Benefit Seen With Armodafinil for Fatigue in Patients With High-Grade Glioma

By

Vicki Moore, PhD

Treatment of fatigue related to high-grade glioma using armodafinil did not show a meaningful benefit over placebo in a phase 3 trial.

Incidence of Advanced Lung Cancer Continues to Decline in the U.S.

During 2014 to 2018, incidence continued to increase slowly for female breast cancer, remained stable for prostate cancer

Light Massage, Music Therapy Effective in Reducing Leukemia-Related Pain and Fatigue

By

Jessica Nye, PhD

Researchers sought to determine the effects of commonly used interventions on 2 significant symptoms experienced by patients with leukemia.

ASCO Releases Guideline for Managing Immune-Related Adverse Events of CAR-T Therapy

By

Jessica Nye, PhD

The guideline focuses on managing treatment of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome in patients undergoing CAR-T therapy for hematologic cancers.

Fosnetupitant Noninferior to Fosaprepitant for Chemotherapy-Induced Nausea and Vomiting

By

Jennifer Larson

A head-to-head comparison was conducted to determine the safety and efficacy of fosnetupitant with fosaprepitant in combination with palonosetron and dexamethasone.

Ankle-Brachial Index, Cardiac Ankle Vascular Index May Indicate Risk of Cardiovascular AEs in Patients With CML Taking TKIs

By

Jessica Nye, PhD

A retrospective analysis of data identified predictors of cardiac adverse events in patients with CML undergoing treatment with tyrosine kinase inhibitors.

Excess Risk of CVD Low With Radiotherapy After Chemotherapy for Early-Stage Hodgkin Lymphoma

By

Jennifer Larson

Researchers sought to determine the potential risk of cardiovascular mortality vs risk of disease recurrence in patients with early-stage HL receiving IFRT after ABVD.